• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?

作者信息

Kaur Navjyot, Pruthvi C R, Rohit Manojkumar

机构信息

Cardiology Unit II, Department of Cardiology, Level-3, Faculty Offices, Advanced Cardiac Center, Post Graduate Institute of Medical Education & Research, Sector-12, Chandigarh, 160012, India.

出版信息

Egypt Heart J. 2021 Mar 16;73(1):26. doi: 10.1186/s43044-021-00152-x.

DOI:10.1186/s43044-021-00152-x
PMID:33725186
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7966569/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e49/7966569/05cd2e79ada4/43044_2021_152_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e49/7966569/05cd2e79ada4/43044_2021_152_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e49/7966569/05cd2e79ada4/43044_2021_152_Fig1_HTML.jpg

相似文献

1
Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?血管紧张素受体脑啡肽酶抑制剂（ARNI）的应用是否会减少射血分数降低的心力衰竭患者对器械治疗的需求？
Egypt Heart J. 2021 Mar 16;73(1):26. doi: 10.1186/s43044-021-00152-x.
2
Implementation of Guideline-Recommended Therapies for Patients With Heart Failure and Reduced Ejection Fraction: A Regional Arab Middle East Experience.《阿拉伯中东部地区指南推荐疗法在射血分数降低的心力衰竭患者中的实施情况》。
Angiology. 2020 May;71(5):431-437. doi: 10.1177/0003319720905742. Epub 2020 Feb 18.
3
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.血管紧张素受体脑啡肽酶抑制剂治疗心力衰竭的最佳实施可降低潜在死亡率。
JAMA Cardiol. 2016 Sep 1;1(6):714-7. doi: 10.1001/jamacardio.2016.1724.
4
Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.心力衰竭和射血分数降低患者中 BNP 和 NT-proBNP 的比较。
Circ Heart Fail. 2020 Feb;13(2):e006541. doi: 10.1161/CIRCHEARTFAILURE.119.006541. Epub 2020 Feb 17.
5
Proteomic Signatures During Treatment in Different Stages of Heart Failure.治疗心力衰竭不同阶段的蛋白质组学特征。
Circ Heart Fail. 2020 Aug;13(8):e006794. doi: 10.1161/CIRCHEARTFAILURE.119.006794. Epub 2020 Jul 29.
6
Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.血管紧张素受体-脑啡肽酶抑制剂：射血分数降低的心力衰竭的新治疗模式。
Int J Cardiol. 2019 Apr 15;281:179-185. doi: 10.1016/j.ijcard.2018.05.124. Epub 2018 Jun 2.
7
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.射血分数降低的心力衰竭的药物治疗：CHAMP-HF 注册研究。
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.
8
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.指南发布对心力衰竭住院患者使用血管紧张素受体脑啡肽酶抑制剂的早期影响。
Am Heart J. 2018 Jun;200:134-140. doi: 10.1016/j.ahj.2018.01.009. Epub 2018 Jan 31.
9
Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.用于射血分数降低的心力衰竭或左心室功能障碍的肾素-血管紧张素-醛固酮系统阻滞剂：网状Meta分析。
Int J Cardiol. 2016 Feb 15;205:65-71. doi: 10.1016/j.ijcard.2015.12.010. Epub 2015 Dec 15.
10
Reduction in pulmonary artery pressures with use of sacubitril/valsartan.使用沙库巴曲缬沙坦降低肺动脉压力。
J Cardiol Cases. 2019 Aug 23;20(5):187-190. doi: 10.1016/j.jccase.2019.08.006. eCollection 2019 Nov.

引用本文的文献

1
The Role of ARNI in Enhancing Outcomes of Cardiac Resynchronization Therapy: A Comprehensive Review.ARNI在改善心脏再同步治疗结局中的作用：一项综述
J Clin Med. 2025 Apr 16;14(8):2743. doi: 10.3390/jcm14082743.
2
Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.埃及专家关于钠-葡萄糖共转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用的意见。
ESC Heart Fail. 2022 Apr;9(2):800-811. doi: 10.1002/ehf2.13811. Epub 2022 Feb 3.

本文引用的文献

1
Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?室性心律失常和 ARNI：鉴于新证据，是否需要重新评估其治疗策略？
Heart Fail Rev. 2022 Jan;27(1):103-110. doi: 10.1007/s10741-020-09991-3.
2
Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.心脏再同步治疗的心力衰竭患者心源性猝死风险的时间趋势：一项系统评价
Eur Heart J. 2020 Jun 1;41(21):1976-1986. doi: 10.1093/eurheartj/ehz773.
3
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
沙库巴曲缬沙坦治疗起始后N末端前B型利钠肽的变化与射血分数降低的心力衰竭患者心脏结构和功能的关联
JAMA. 2019 Sep 17;322(11):1085-1095. doi: 10.1001/jama.2019.12821.
4
Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?沙库巴曲缬沙坦的抗心律失常作用：是临床改善的原因还是结果？
J Clin Med. 2019 Jun 18;8(6):869. doi: 10.3390/jcm8060869.
5
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.沙库巴曲缬沙坦可减少心力衰竭射血分数降低患者的室性心律失常，同时逆转左心室重构。
Clin Res Cardiol. 2019 Oct;108(10):1074-1082. doi: 10.1007/s00392-019-01440-y. Epub 2019 Feb 20.
6
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.血管紧张素-脑啡肽酶抑制剂在急性失代偿性心力衰竭中的应用。
N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.
7
Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.在植入式除颤设备连续远程监测下，比较血管紧张素-脑啡肽酶抑制与血管紧张素抑制对射血分数降低患者室性心律失常的影响。
Heart Rhythm. 2018 Mar;15(3):395-402. doi: 10.1016/j.hrthm.2017.11.012. Epub 2017 Nov 14.
8
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2017年美国心脏病学会/美国心脏协会/美国心力衰竭学会对2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南的重点更新：美国心脏病学会/美国心脏协会临床实践指南特别工作组及美国心力衰竭学会的报告
Circulation. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509. Epub 2017 Apr 28.
9
Should Nonischemic CRT Candidates Receive CRT-P or CRT-D?非缺血性心脏再同步化治疗候选者应接受心脏再同步化治疗-起搏器（CRT-P）还是心脏再同步化治疗-除颤器（CRT-D）？
J Am Coll Cardiol. 2017 Apr 4;69(13):1679-1682. doi: 10.1016/j.jacc.2017.01.044.
10
Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis.用于非缺血性心肌病的植入式心脏复律除颤器：一项更新的荟萃分析。
Circulation. 2017 Jan 10;135(2):201-203. doi: 10.1161/CIRCULATIONAHA.116.026056. Epub 2016 Dec 19.